Therefore, haemodynamic factors such as systemic and glomerular hypertension, and the vasoactive hormone, angiotensin II have become the major therapeutic target for DN (Cooper, 1998; Wong et al., 2007). This evidence concerns the gene AGT and liver dysplastic nodule.